Feb 25th 2013 - Edison Investment Research today published a report on quickview entitled "Turning A Corner". In summary, the report says:
Zeltia is approaching a material catalyst this year in the form of the read-out from its Phase II study of lurbinectedin (PM01183) in platinum resistant ovarian cancer. If positive, this could form the basis of a licensing deal that could transform Zeltia’s fortunes. This, and the more positive sales outlook for Yondelis (trabectedin), which has been hampered by recent Doxil supply shortages, should support further pipeline development and ultimately help Zeltia transition into a cancer pure-play.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »